 |
|
Review
Survey of malignant tumours
Wheat germ is a valuable nutritional source. In addition to proteins of high nutritional importance, tocopherol and B vitamins, it contains quinone compounds in a metoxy-substituted glycolisated form. Quinones are components present in several essential reaction chains in the organism, though it was also recognized that quinones are predominantly absent in malignant tumour tissue. On the basis of this fact, it was demonstrated that quinones are capable of inhibiting the growth of Ehrlich ascitic tumour, the effect being attributable to the delivery of free semiquinone- and ascorbate radicals. In 1991, a new wheat germ extract containing an optimal ratio of benzoquinones was produced by means of fermentation. The technology was translated onto an industrial level and it was at that moment that Avemar (generic name: MSC) began its success story. The above introduction should make clear how we arrived at the treatment of malignant tumours from wheat germ. While benzoquinone compounds are of vital importance to Avemar's mode of action, they are not, on their own, capable of producing even a small proportion of Avemar's proven effects. Untreated wheat germ is also unable to produce such effects. Only the entire complex of fermented wheat germ extract contained in Avemar is capable of producing the effects thus far demonstrated.
The results of animal experiments and the product's effect mechanism have been written about elsewhere. Avemar did not influence the anti-tumour effect of cyctostatics widely used in clinical practice, though numerous tests demonstrated Avemar's synergistic metastasis-inhibiting effect when combined with several cytostatics. Its clinical application is facilitated by the lack of common side effects, notably bone marrow damage, associated with cytostatics. Furthermore, animal experiments demonstrated its ability to restore bone marrow damaged by cyclophosphamide and radiotherapy.
Avemar is therapeutically categorised as a nutriment which, when applied within the framework of supportive therapy, works as a complementary treatment to the standard active oncotherapy procedures (surgery, radiotherapy, chemotherapy, immuno-therapy), though its ability to inhibit tumours has been proven. Its use is also recommended between therapy sessions and after the completion of active oncotherapy; the current state of knowledge suggests that, in its current composition, Avemar can be taken for an unlimited period of time.
The product was commercially launched in 1998, its anti-tumour effects being demonstrated by clinical studies conducted with patients suffering from colorectal cancer, squamous cell cancer of the oral cavity and melanoma of the skin. Cases of successful application in the treatment of breast cancer, primary hepatocellular carcinoma, cancer of the prostate, bladder and kidney, and head and neck tumours have also been reported.
In addition to its direct anti-tumour effect, Avemar also improved the quality of life in lung cancer patients. Owing to its multiple effects on the immune system, it also decreased occurrences of febrile neutropenia in children suffering from malignant tumours who had been treated with intensive chemotherapy.
|
 |
|
 |
